Hydroxychloroquine denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for hydroxychloroquine are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Hydroxychloroquine as Duplicate Therapy

Humana's duplicate-therapy denial for hydroxychloroquine typically occurs when the patient is already dispensing another antimalarial or immunomodulatory agent that Humana's utilization-management system classifies as therapeutically overlapping. In the real world, hydroxychloroquine is used in rheumatology (lupus, rheumatoid arthritis) and other autoimmune conditions, and combination regimens are sometimes clinically indicated — but they require explicit documentation explaining why two agents in a related class are simultaneously necessary. The denial is not a judgment that hydroxychloroquine is inappropriate; it is a flag that the clinical rationale for concurrent use has not been established in the record.

## Your Right to Appeal

• ACA §2719 / External Review: After internal exhaustion, you may request independent external review, generally within approximately four months of the denial date.
• ERISA §503: Humana must provide the specific duplicate-therapy criteria applied and allow a full-and-fair review.
• Expedited review: Available if clinical urgency (e.g., active lupus flare) makes standard timelines dangerous.

## What to Gather

1. Prescriber medical-necessity letter — the cornerstone of this appeal. The prescriber must explain why both agents are required simultaneously, what each one addresses, and why monotherapy is insufficient. 2. Diagnosis confirmation — chart documentation of the underlying condition (e.g., systemic lupus erythematosus, rheumatoid arthritis) with disease-activity notes. 3. Treatment history with dates and outcomes — showing how the current regimen evolved and why it represents the current standard of care for this patient. 4. Applicable guideline reference — the prescriber should reference the relevant professional-society guideline (e.g., applicable ACR or AAD guidance) that supports combination use for the patient's diagnosis. 5. Distinction between agents — a brief clinical statement that the concurrent drug is not a therapeutic substitute for hydroxychloroquine in this patient's regimen.

## Criteria-Mapping Approach

Obtain Humana's published clinical coverage policy or step-therapy/duplicate-therapy criteria for hydroxychloroquine. For each criterion, provide a direct chart-based answer. The appeal should make clear that the prescriber's regimen is deliberate and guideline-informed, not inadvertent duplication.

## Next Steps

File the internal appeal with the prescriber's letter as the lead document. If Humana upholds the denial, request external review — independent reviewers with rheumatology or internal-medicine expertise frequently recognize that combination regimens in autoimmune disease are standard practice.